Aligos Therapeutics (ALGS) Net Margin (2021 - 2026)
Aligos Therapeutics (ALGS) reported Net Margin of 814.13% for Q1 2026, down 1466880.0% on a YoY basis from N/an in Q1 2025, and up 93.08% quarter-over-quarter from 11763.91% in Q4 2025.
Aligos Therapeutics (ALGS) Net Margin (2021 - 2026) Analysis & Trends
Aligos Therapeutics has reported Net Margin for 6 years, with the latest figure at 814.13% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 1466880.0% year-over-year to 814.13%; the trailing twelve-month figure through Mar 2026 stood at 1919.68% (down 26974.0% YoY), and the FY2025 full-year result was 1106.72%, up 252692.0% from the prior year.
- Net Margin for Q1 2026 stood at 814.13%, up from 11763.91% in the prior quarter.
- The five-year high for Net Margin was 13854.66% in Q1 2025, with the low at 13556.11% in Q4 2024.
- Historically, Net Margin has averaged 1944.32% across 5 years, with a median of 888.7% in 2023.
- Annual changes were most pronounced in 2025 — Net Margin soared 1887815 bps — and 2026, when it slumped 1466880 bps.
- Aligos Therapeutics' Net Margin stood at 618.77% in 2022, then fell by 18 bps to 730.35% in 2023, then tumbled by 1756 bps to 13556.11% in 2024, then advanced by 13 bps to 11763.91% in 2025, then soared by 93 bps to 814.13% in 2026.
- The last three Net Margin figures came in at 814.13% (Q1 2026), 11763.91% (Q4 2025), and 4256.01% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Aligos Therapeutics | 51.70 Mn | -28.13 Mn | - | -814.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -814.13% |
| Dec 31, 2025 | -11,763.91% |
| Sep 30, 2025 | -4,256.01% |
| Jun 30, 2025 | -1,643.83% |
| Mar 31, 2025 | 13,854.66% |
| Dec 31, 2024 | -13,556.11% |
| Sep 30, 2024 | -1,540.72% |
| Jun 30, 2024 | 477.00% |
| Mar 31, 2024 | -5,023.49% |
| Dec 31, 2023 | -730.35% |
| Sep 30, 2023 | -837.56% |
| Jun 30, 2023 | -437.61% |
| Mar 31, 2023 | -888.70% |
| Dec 31, 2022 | -618.77% |
| Mar 31, 2022 | -1,385.26% |
| Dec 31, 2021 | -10,276.29% |
| Sep 30, 2021 | -2,155.11% |
| Jun 30, 2021 | -1,929.97% |
| Mar 31, 2021 | -3,041.10% |